Literature DB >> 11699394

Effect of immunostimulatory CpG-oligonucleotides in chronic lymphocytic leukemia B cells.

T Decker1, C Peschel.   

Abstract

Bacterial DNA and phosphothioate oligonucleotides containing a CpG motif (CpG-ODN) can activate cells of the immune system such as monocytes, dendritic cells and B cells. Protective immune responses against pathogens and tumor cells were observed in murine models when mice were treated with CpG-ODN. Recent results have demonstrated strong activation of human immune cells as well. Apart from stimulating cells of the immune system, CpG ODN have many direct effects on B-CLL cells such as upregulation of costimulatory molecules, cell cycle entry and upregulation of potential target antigens for antibody therapy. Therefore, CpG-ODN appear to be attractive compounds to be included into new therapeutic strategies like tumor cell vaccination and adoptive T cell transfer or therapy with monoclonal antibodies. In this review, the effects of CpG-ODN on B-CLL cells are summarized and potential therapeutic applications of CpG-ODN in chronic lymphocytic leukemia are discussed.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11699394     DOI: 10.3109/10428190109064586

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  4 in total

1.  B-chronic lymphocytic leukemia cells and other B cells can produce granzyme B and gain cytotoxic potential after interleukin-21-based activation.

Authors:  Bernd Jahrsdörfer; Sue E Blackwell; James E Wooldridge; Jian Huang; Melinda W Andreski; Laura S Jacobus; Christiana M Taylor; George J Weiner
Journal:  Blood       Date:  2006-06-29       Impact factor: 22.113

2.  Divergent synthetic nucleotide motif recognition pattern: design and development of potent immunomodulatory oligodeoxyribonucleotide agents with distinct cytokine induction profiles.

Authors:  Ekambar R Kandimalla; Lakshmi Bhagat; Daqing Wang; Dong Yu; Fu-Gang Zhu; Jimmy Tang; Hui Wang; Ping Huang; Ruiwen Zhang; Sudhir Agrawal
Journal:  Nucleic Acids Res       Date:  2003-05-01       Impact factor: 16.971

3.  Toll-like Receptors in Chronic Lymphocytic Leukemia.

Authors:  Marta Muzio; Eleonora Fonte; Federico Caligaris-Cappio
Journal:  Mediterr J Hematol Infect Dis       Date:  2012-08-09       Impact factor: 2.576

4.  A novel ex vivo high-throughput assay reveals antiproliferative effects of idelalisib and ibrutinib in chronic lymphocytic leukemia.

Authors:  Daniel Primo; Lydia Scarfò; Aliki Xochelli; Mattias Mattsson; Pamela Ranghetti; Ana Belén Espinosa; Alicia Robles; Julian Gorrochategui; Joaquín Martínez-López; Javier de la Serna; Marcos González; Alberto Chaparro Gil; Eduardo Anguita; Sandra Iraheta; Veerendra Munugalavadla; Christophe Quéva; Stacey Tannheimer; Richard Rosenquist; Kostas Stamatopoulos; Joan Ballesteros; Paolo Ghia
Journal:  Oncotarget       Date:  2018-05-25
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.